Scinai Immunotherapeutics Ltd. (SCNI) — 20-F Filings
All 20-F filings from Scinai Immunotherapeutics Ltd.. Browse 2 Foreign Annual Report reports with AI-powered summaries and risk analysis.
20-F Filings (2)
-
Scinai Faces Going Concern Amidst Persistent Losses, Cash Dwindles
— Apr 1, 2026 Risk: high
Scinai Immunotherapeutics Ltd. (SCNI) reported significant operating losses of $7.5 million in 2025, an improvement from $8.6 million in 2024 and $9.7 million i -
Scinai Immunotherapeutics Files 2024 Annual Report
— May 7, 2025 Risk: medium
Scinai Immunotherapeutics Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, formerly known as BiondVax Pharmac
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX